Reduced risk of colorectal cancer with use of oral bisphosphonates: A systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 31, Issue 5, 2013, Pages 623-630

  Thosani, Nirav ^a,b   Thosani, Sonali N ^b,c   Kumar, Sheetanshu ^b   Nugent, Zoann ^d   Jimenez, Camilo ^b   Singh, Harminder ^d   Guha, Sushovan ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

CANCER RISK; CASE CONTROL STUDY; COLORECTAL CANCER; DOSE RESPONSE; HUMAN; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, ORAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ODDS RATIO; RISK REDUCTION BEHAVIOR;

EID: 84875466027     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.9530     Document Type: Review

References (44)

1. Compston J, Cooper A, Cooper C, et al: Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62: 105-108, 2009
2. Watts NB, Bilezikian JP, Camacho PM, et al: American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16: 1-37, 2010 (suppl 3)
3. Rosen CJ: Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353: 595-603, 2005
4. Aapro M, Abrahamsson PA, Body JJ, et al: Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 19: 420-432, 2008
5. Heras P, Karagiannis S, Kritikos K, et al: Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 16: 539-542, 2007
6. Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102: 799-802, 2010
7. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009
8. Pavlakis N, Schmidt R, Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474, 2005
9. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al: The antineoplastic role of bisphosphonates: From basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003 (Pubitemid 37304600)
10. Santini D, Virzi V, Fratto ME, et al: Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 10: 46-54, 2010
11. Luckman SP, Hughes DE, Coxon FP, et al: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589, 1998 (Pubitemid 28163009)
12. Wiemer AJ, Hohl RJ, Wiemer DF: The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 9: 526-542, 2009
13. Sassa S, Okabe H, Nemoto N, et al: Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 29:4615- 4619, 2009
14. Sewing L, Steinberg F, Schmidt H, et al: The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13: 782-789, 2008
15. Todaro M, D'Asaro M, Caccamo N, et al: Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182:7287- 7296, 2009
16. Stroup DF, Berlin JA, Morton SC, et al: Metaanalysis of observational studies in epidemiology: A proposal for reporting - Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012, 2000 (Pubitemid 30214957)
17. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. http:// www.ohri.ca/programs/clinical-epidemiology/oxford .asp
18. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986 (Pubitemid 17189972)
19. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539- 1558, 2002 (Pubitemid 34746062)
20. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003 (Pubitemid 37088507)
21. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997 (Pubitemid 27387172)
22. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463, 2000 (Pubitemid 30422636)
23. Sterne JA, Egger M: Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol 54: 1046-1055, 2001 (Pubitemid 32888370)
24. Sterne JA, Egger M, Smith GD: Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105, 2001 (Pubitemid 32681979)
25. Group USCSW: United States Cancer Statistics: 1999-2007. Incidence and Mortality Web-based Report. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2010. www.cdc.gov/uscs
26. Green J, Czanner G, Reeves G, et al: Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort. BMJ 341:c4444, 2010
27. Rennert G, Pinchev M, Rennert HS, et al: Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29: 1146-1150, 2011
28. Singh H, Nugent Z, Demers A, et al: Exposure to bisphosphonates and risk of colorectal cancer: A population-based nested case-control study. Cancer 118: 1236-1243, 2012
29. Vestergaard P: Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 89: 434-441, 2011
30. Khalili H, Huang ES, Ogino S, et al: A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol 30: 3229-3233, 2012
31. Pazianas M, Abrahamsen B, Eiken PA, et al: Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate- Danish National Register Based Cohort Study. Osteoporos Int 23: 2693-2701, 2012
32. Watts NB, Diab DL: Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95: 1555-1565, 2010
33. Green JR: Bisphosphonates: Preclinical review. Oncologist 9: 3-13, 2004 (suppl 4) (Pubitemid 39363164)
34. Mahtani R, Jahanzeb M: Bisphosphonates as anticancer therapy for early breast cancer. Clin Breast Cancer 10: 359-366, 2010
35. Meunier PJ, Chapuy MC, Alexandre C, et al: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 2: 489-492, 1979 (Pubitemid 9256691)
36. Santini D, Vincenzi B, Dicuonzo G, et al: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893-2897, 2003 (Pubitemid 36993246)
37. Senaratne SG, Mansi JL, Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86: 1479-1486, 2002 (Pubitemid 34548073)
38. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000 (Pubitemid 30395820)
39. Cardwell CR, Abnet CC, Cantwell MM: Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304: 657-663, 2010
40. Dixon WG, Solomon DH: Bisphosphonates and esophageal cancer: A pathway through the confusion. Nat Rev Rheumatol 7: 369-372, 2011
41. Khosla S, Burr D, Cauley J, et al: Bisphosphonateassociated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491, 2007 (Pubitemid 351229318)
42. Odvina CV, Levy S, Rao S, et al: Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 72: 161-168, 2010
43. Goodman SN: Have you ever meta-analysis you didn't like? Ann Intern Med 114: 244-246, 1991
44. Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 53: 1119-1129, 2000